Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver

Drug Metabolism and Disposition

Volumn 27, Issue 3, 1999, Pages 395-402

  Yamano, Katsuhiro ^a,c   Yamamoto, Koujirou ^b   Kotaki, Hajime ^c   Sawada, Yasufumi ^d   Iga, Tatsuji ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; MIDAZOLAM MALEATE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG UPTAKE; INHIBITION KINETICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFUNGAL AGENTS; BLOOD PROTEINS; HYPNOTICS AND SEDATIVES; ITRACONAZOLE; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDAZOLAM; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0032941364     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ahonen J, Olkkola KT and Neuvonen P (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25:261-270.
3. Baur H, Kasperek S and Pfaff E (1975) Criteria of viability of isolated liver cells. Hoppe-Seylers Z Physiol Chem 356:827-838.
4. Beckman JT, Aranko K, Himberg JJ and Olkkola KT (1994) A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 46:551-555.
5. Ervine CM, Matthew DE, Brennan B and Houston JB (1996) Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors: Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab Dispos 24:211-215.
6. Fee JPH, Collier PS, Howard PJ and Dundee JW (1987) Cimelidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 41:80-84.
7. Fujieda Y, Yamaoka K, Ito T and Nakagawa T (1996) Local absorption kinetics of levofloxacin from intestinal tract into portal vein in concentration difference. Pharm Res (NY) 13:1201-1204.
8. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
9. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
10. Hoffman DJ, Seifert T, Borre A and Nellans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res (NY) 12:889-894.
11. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
12. Meijer DKF, Mol WEM, Muller M and Kurz G (1990) Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18:35-70.
13. Miyauchi S, Sawada Y, Iga T, Hanano M and Sugiyama Y (1993) Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm Res (NY) 10:434-440.
14. Nakamura H, Sano H, Yamazaki M and Sugiyama Y (1994) Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type 1 system. J Pharmacol Exp Ther 269: 1220-1227.
15. Olkkola KT, Ahonen J and Neuvonen PJ (1996) The effect of the systemic antimycotics. itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
16. Olkkola KT, Aranko K. Luurila H, Hiller A, Saarnivaara L, Himberg JJ and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
17. Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
18. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, Mcvicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
19. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G and Maurel P (1990) Cyclosporin A drug interactions screening for inducers and inhibitors of cytochrome P450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
20. Sawada Y, Takanaga H and Iga T (1996) Desirable state of drug interaction section in package insert circulars. J Pract Pharm 47:1535-1565 (in Japanese).
21. Sugiyama Y and Iwatsubo T (1996) Alteration of pharmacokinetic features caused by drug interaction. Xenobio Metabol Dispos 11:286-293 (in Japanese).
22. Tabata K, Yamaoka K, Fukuyama T and Nakagawa T (1995) Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 12:880-888.
23. Takedomi S, Matsuo H, Yamano K, Yamamoto K, Iga T and Sawada Y (1998) Quantitative prediction of the interaction of midazolam and histamine H2-receptor antagonist interaction in rats. Drug Metab Dispos 26:318-323.
24. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
25. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Prichard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effect of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
26. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
27. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res (NY) 13:497-513.
28. Yuan J, Yang DC, Birkmeier J and Stolzenbach J (1995) Determination of protein binding by in vitro charcoal adsorption. J Pharmacokinet Biopharm 23(Suppl 1):41-55.
29. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res (NY) 11:921-924.